USFDA nod to Zydus Lifesciences Migraine drug Topiramate Extended Release
The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.;
Ahmedabad: Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg (USRLD: Qudexy XR Extended-Release capsules).
Topiramate Extended-Release capsule is indicated to prevent and control seizures in people with epilepsy. It may also be used to prevent migraine headaches.
The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.
Topiramate Extended-Release capsule had annual sales of USD 68.8 mn in the United States, according to IQVIA data (IQVIA MAT Sep 2022). The group now has 335 approvals and has so far filed over 431* ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Lifesciences appoints Akhil Monappa, Upasana Kamineni Konidela as new Independent Directors
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.